Daytime versus evening infusions of immune checkpoint inhibitors

Affiliations

¹ UPR "Chronotherapy, Cancers and Transplantation", CNRS Campus, Faculty of Medicine, Paris-Saclay University, Villejuif, 94800, France; Department of Medical Oncology, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Villejuif, France; Cancer Chronotherapy Team, Warwick Medical School, Coventry, UK. Electronic address: francis.levi@inserm.fr.

Comment

Francis Lévi. Lancet Oncol. 2021 Dec.

. 2021 Dec;22(12):1648-1650.

doi: 10.1016/S1470-2045(21)00607-0. Epub 2021 Nov 12.

¹ UPR "Chronotherapy, Cancers and Transplantation", CNRS Campus, Faculty of Medicine, Paris-Saclay University, Villejuif, 94800, France; Department of Medical Oncology, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris, Villejuif, France; Cancer Chronotherapy Team, Warwick Medical School, Coventry, UK. Electronic address: francis.levi@inserm.fr.

No abstract available

Conflict of interest statement

I declare no competing interests

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, Lawson DH, Khan MK, Kudchadkar RR, Buchwald ZS. Qian DC, et al. Lancet Oncol. 2021 Dec;22(12):1777-1786. doi: 10.1016/S1470-2045(21)00546-5. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780711 Clinical Trial.